Copenhagen, Denmark—Side effect management is one of the more important tasks specialty pharmacists need to grapple with when managing patients on oral chemotherapy agents. But according to one recent study, the incidence of adverse effects associated with targeted chemotherapy—one of the fastest-growing types of cancer treatment—may be higher than the literature suggests.
Indeed, more than half of 81 trials leading to the approval of a targeted therapy were judged to not be